BlackRock Institutional Trust’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

BlackRock Institutional Trust’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.41M	Hold	345,940	–	–	﹤0.01%	3176
2016 Q3	$1.29M	Hold	345,940	–	–	﹤0.01%	3206
2016 Q2	$1.18M	Sell	345,940 -222,527	-39%	-$1.02M	﹤0.01%	3253
2016 Q1	$3.02M	Buy	568,467 +39,408	+7%	+$315K	﹤0.01%	2876
2015 Q4	$6.51M	Buy	529,059 +65,005	+14%	+$868K	﹤0.01%	2582
2015 Q3	$6.78M	Sell	464,054 -35,123	-7%	-$607K	﹤0.01%	2543
2015 Q2	$9.73M	Sell	499,177 -9,819	-2%	-$190K	﹤0.01%	2419
2015 Q1	$9.21M	Buy	508,996 +2,593	+0.5%	+$58.4K	﹤0.01%	2443
2014 Q4	$12M	Buy	506,403 +18,909	+4%	+$437K	﹤0.01%	2266
2014 Q3	$11.8M	Buy	487,494 +22,924	+5%	+$596K	﹤0.01%	2221
2014 Q2	$13.1M	Buy	464,570 +45,046	+11%	+$1.35M	﹤0.01%	2259
2014 Q1	$14.3M	Buy	419,524 +15,841	+4%	+$541K	﹤0.01%	2193
2013 Q4	$7.71M	Buy	403,683 +51,183	+15%	+$932K	﹤0.01%	2569
2013 Q3	$5.71M	Buy	352,500 +11,993	+4%	+$139K	﹤0.01%	2666
2013 Q2	$3.58M	Buy	+340,507	New	+$3.99M	﹤0.01%	2844

Other funds holding CTIC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Institutional Trust's CTIC Position: Q4 2016 in Review

BlackRock Institutional Trust held its CTI BioPharma Corp. (DE) Common Stock (CTIC) position steady in Q4 2016 at 345,940 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3176.

BlackRock Institutional Trust first reported a position in CTIC in Q2 2013 and has held it in 15 quarters since. The position peaked at $14.3M in Q1 2014. 58 funds tracked by Wall St. Rank hold CTIC as of Q4 2016.

BlackRock Institutional Trust held 345,940 shares of CTI BioPharma Corp. (DE) Common Stock worth $1.41M as of Q4 2016.
BlackRock Institutional Trust left its CTI BioPharma Corp. (DE) Common Stock share count unchanged in Q4 2016.
CTI BioPharma Corp. (DE) Common Stock made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3176 holding.
BlackRock Institutional Trust first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's CTI BioPharma Corp. (DE) Common Stock position peaked at $14.3M in Q1 2014.
58 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.